We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Alzheimer’s Progression Blood Test Gains U.S. Patent Ahead of Planned Launch

By LabMedica International staff writers
Posted on 22 Oct 2026

Alzheimer’s disease is the most common cause of dementia, accounting for an estimated 60–70% of cases worldwide. More...

Its progressive effects on memory, thinking, behavior, and daily functioning underscore the importance of identifying people at risk early. To support this assessment, a newly patented blood-based prognostic test aims to help clinicians evaluate the likelihood of progression to Alzheimer’s disease, including in patients with mild cognitive impairment.

Diadem SpA (Milan, Italy) has been awarded a U.S. patent extending protection for its proprietary AlzoSure prognostic biomarker technology ahead of the planned commercial launch of the AlzoSure Predict clinical test. Building on a U.S. patent granted in January 2019, the new patent covers specified methods for detecting and measuring U-p53AZ in biological samples, including blood, serum, and plasma. The assay uses proprietary antibody technology to measure blood levels of this conformational variant of the p53 protein, which is associated with Alzheimer’s disease.

Published clinical studies have demonstrated the test’s ability to predict clinical progression in Alzheimer’s disease up to six years before the onset of dysfunction. In a longitudinal clinical validation study, AlzoSure Predict achieved an area under the receiver operating characteristic curve (AUC) of more than 0.98, distinguishing individuals who progressed through clinical stages of Alzheimer’s disease from those who did not.

“As we prepare for the commercial launch of AlzoSure Predict, securing protection for our methods of detecting U-p53AZ is an important step. The ability to predict clinical progression in Alzheimer’s disease, and to identify patients who are unlikely to progress, could help clinicians make more informed decisions about further investigation, monitoring, and care. This is particularly important as new treatment options make earlier identification of patients at risk increasingly relevant,” said Shmuel (Sam) Agus, MD, Chief Medical Officer of Diadem.

Related Links
Diadem


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Immunoassay Analyzer
SuperFlex™
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The MIRAM GAGome Kit quantifies urine CS disaccharides by UHPLC-MS/MS, supporting exploratory and translational research across disease areas. (Photo courtesy of Elypta)

Study Finds Urine Biomarker Score Improves Five-Year Cancer Risk Prediction

Cancer risk stratification in healthy adults often relies on established factors such as age and smoking history. However, several cancers highlighted in the study, including pancreatic, kidney, and brain... Read more

Molecular Diagnostics

view channel
Image: A blood test measuring circulating tumor DNA may help identify men with hormone-resistant oligoprogressive prostate cancer most likely to benefit from stereotactic body radiotherapy (Image Credit: Adobe Stock)

Blood Test Identifies Candidates for Targeted Radiotherapy in Advanced Prostate Cancer

Advanced prostate cancer can progress despite hormone-based treatment, with imaging sometimes revealing only limited areas of active disease. For men with hormone-resistant oligoprogressive prostate cancer,... Read more

Hematology

view channel
Image: These new ANC reference ranges can help clinicians more accurately interpret neutrophil counts, reduce unnecessary testing and treatment interruptions, and help support more equitable care. (Photo courtesy of the American Society of Hematology)

New Reference Ranges Clarify Normal Neutrophil Counts in Duffy-Null Patients

Duffy-null status is a common genetic trait associated with naturally lower circulating white blood cell counts. It affects about 10% of the U.S. population and more than 66% of people with African or... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: VITEK PRO combines microbial identification and antimicrobial susceptibility testing on a single platform to support routine microbiology workflows and antibiotic selection. (Photo courtesy of bioMérieux)

Automated Microbial Identification and Susceptibility System Gains FDA Clearance

Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.